A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis

Exclusion Criteria

• •Patient has a possible or confirmed diagnosis of Crohn's Disease or other forms of inflammatory bowel disorders
• •Patient has a persistent fever of ≥ 38.3°C
• •Patient has current signs or symptoms of infection
• •Patient has any immunosuppressant condition
• •Patient has a known malignancy within 5 years prior to Screening
• •Patient who has a medical history of drug abuse or alcohol abuse
• •Patient who, in the opinion of the Investigator, has a clinically significant co-morbid disease
• •Patient has hepatic failure
• •Patient is pregnant or plans a pregnancy within the study period
• •Patient has no previous history of treatment for ulcerative colitis (treatment-naïve patient)
• •Patient has ongoing or failed treatment for ulcerative colitis with calcineurin inhibitor
• •Patient has received biologic medication
• •Patient has received antibiotics within 4 weeks prior to Visit 2
• •Patient is unable to stop previous antibiotics treatment during study period
• •Patient has received probiotics within 2 weeks prior to Visit 2
• •Patient with history of major surgery in any region of the gastrointestinal tract
• •Patient has received any investigational product or participated in another clinical trial
• •Patient has a stool culture or other examination positive for an enteric pathogen
• •Patient tests positive for CMV by PCR test at Screening
• •Patient tests positive for HIV at Screening